UK markets closed

HYLORIS PHARMA. S.A. (52U.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
15.30+0.35 (+2.34%)
As of 8:20AM CET. Market open.
Full screen
Previous close14.95
Open15.30
Bid15.30 x N/A
Ask15.80 x N/A
Day's range15.30 - 15.30
52-week range9.32 - 17.10
Volume500
Avg. volume38
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic® IV

    PDUFA date set on 30 June 2022, ahead of the August to September 2022 timeframe initially expected Liège, Belgium – 15 November 2021, 7:00 am CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the U.S. Food and Drug Administration (FDA) has set the Prescription Drug User Fee Act date (PDUFA) for the New Drug Application (NDA) for Maxigesic® IV on 30 Jun

  • Globe Newswire

    Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer

    Strategic partnership with Pleco Therapeutics for a novel combination product of chelating agents in AML and SCLCHyloris to commit €1 million, convertible into equity, plus pre-defined R&D funding through to regulatory submission Liège, Belgium – 10 November 2021, 7:00am CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has entered into a strategic

  • Globe Newswire

    Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic® IV in Post-Operative Pain

    Hyloris to receive $1 million milestone paymentMaxigesic® IV has the potential to combat the opioid crisis in the U.S. Liège, Belgium – 1 November 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Maxigesic® IV, a novel, unique combination of 1000mg paracetamol